Volume 28, Number 12—December 2022
CME ACTIVITY - Research
Acinetobacter baumannii among Patients Receiving Glucocorticoid Aerosol Therapy during Invasive Mechanical Ventilation, China
Table 3
Multivariate analysis of risk factors for Acinetobacter baumannii among propensity-matched patient cohort during invasive mechanical ventilation, China*
Variables | p value | Hazard ratio (95% CI) |
---|---|---|
Underlying conditions | ||
Cardiovascular diseases | 0.117 | 1.361 (0.926–2.001) |
Chronic renal insufficiency | 0.800 | 1.052 (0.712–1.554) |
Type 2 diabetes mellitus | 0.243 | 1.271 (0.850–1.899) |
Current or former smoker |
0.051 |
1.442 (0.998–2.083) |
Treatment | ||
Glucocorticoid aerosol inhalation | 0.032 | 1.489 (1.036–2.141) |
Broad-spectrum antimicrobial drugs, >7 d | 0.004 | 6.315 (2.543–13.921) |
Invasive mechanical ventilation, >5 d | <0.001 | 2.388 (1.614–3.534) |
Vasopressor treatment, >3 d |
0.501 |
1.188 (0.719–1.963) |
APACHE II score | 0.363 | 1.014 (0.984–1.045) |
*Only variables with p<0.1 in univariate analysis of the propensity-matched cohort were included. APACHE II, Acute Physiology and Chronic Health Evaluation II; COPD, chronic obstructive pulmonary disease.
1These authors contributed equally to this article.